Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Ryan Spencer
|
| gptkbp:collaboratedWith |
Clover Biopharmaceuticals
Medigen Vaccine Biologics |
| gptkbp:developedBy |
adjuvants for vaccines
vaccines for hepatitis B |
| gptkbp:focusesOn |
vaccines
immunotherapy |
| gptkbp:foundedIn |
1996
|
| gptkbp:headquartersLocation |
gptkb:Emeryville,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dynavax Technologies
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:involvedIn |
COVID-19 vaccine development
|
| gptkbp:notableProduct |
CpG 1018 adjuvant
HEPLISAV-B |
| gptkbp:numberOfEmployees |
approximately 300 (2023)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
DVAX
|
| gptkbp:website |
https://www.dynavax.com/
|
| gptkbp:bfsParent |
gptkb:Hepatitis_B_Vaccine
|
| gptkbp:bfsLayer |
6
|